Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 227 Billion Yen for Dual Use Manufacturing Facilities: FY2021 METI Extra Budget
November 29, 2021
- MHLW Earmarks 608 Billion Yen for COVID-19 Drug Initiatives: FY2021 Extra Budget
November 29, 2021
- Idorsia’s Cerebral Vasospasm Drug, Efient Label Expansion Clear PAFSC
November 29, 2021
- PMDA Reviewing Safety Risk of Imusera/Gilenya
November 29, 2021
- Olumiant Gets Sakigake Tag for Type I IFN Autoinflammatory Diseases
November 29, 2021
- PMDA Plans to Cut Review Fees for Fertility Treatments in January
November 26, 2021
- Japan Approves Jardiance for Heart Failure, Label Expansions for Opdivo and Keytruda
November 26, 2021
- Verify Adjustment Rate, Review Pricing Rule with Cost-Benefit Standpoint: CEFP
November 26, 2021
- Pharma Pushes 2% Adjustment Rate Plus Certain Range in 2022 Drug Price Revision
November 26, 2021
- Sanofi’s Praluent to Be Taken Off Japan NHI Price List Next Spring
November 26, 2021
- Medical Fee, Drug Price Revisions Major Topics for FY2022 Budget: MHLW
November 25, 2021
- LDP Health Panel Chief Vows to Push Development of Japan-Made Vaccines and Drugs
November 25, 2021
- 1st Lucentis Biosimilar, 3rd Humira Follow-On Get Japan Listing
November 24, 2021
- BMS’ Second CAR-T Therapy Ide-Cel Up for PAFSC Review on Dec. 6
November 24, 2021
- Orphan Status Granted to Daiichi Sankyo’s Valemetostat Tosilate, 2 Other APIs
November 24, 2021
- Japan OKs 56 Trillion Yen Stimulus Package, Spells Out Support for Japan-Made Drugs and Vaccines
November 22, 2021
- Amitiza Gets Label Update for Opioid-Induced Constipation
November 22, 2021
- Japan to Go Ahead with Procedures for Pediatric Vaccination without Preconceptions: Minister
November 22, 2021
- Japan Sets Up Vaccine Team Confab of Sr. Vice Ministers
November 22, 2021
- Amgen’s KRAS Inhibitor, MSD’s Cough Drug Up for PAFSC Review on Dec. 2
November 19, 2021
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…